Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026

Data Readoutpositiveaglatimagene besadenovecPositive

AI Analysis

Summary

Candel Therapeutics announced Phase 3 biomarker data for aglatimagene besadenovec in localized prostate cancer showing sustained immune remodeling more than two years post-treatment, presented at ASTRO 2026.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Sustained immune remodeling more than two years after treatment in Phase 3 clinical trial

Importance:6/10

Sentiment:

0.70

Phase 3 dataImmunotherapyProstate cancerBiomarker dataConference presentation

Related Companies

$CADL

Read the original article

Published by GlobeNewswire Clinical Studies on September 30, 2026 12:05 PM

Read Original